What is the current valuation of the neurodegenerative disease market in Germany?

The market valuation was $3500.0 Million in 2024. Read More

What is the projected market size for neurodegenerative diseases in Germany by 2035?

The market is expected to reach $7600.0 Million by 2035. Read More

What is the expected CAGR for the neurodegenerative disease market in Germany from 2025 to 2035?

The expected CAGR during the forecast period is 7.3%. Read More

Which companies are the key players in the Germany neurodegenerative disease market?

Key players include Biogen, Eli Lilly, Roche, Novartis, AstraZeneca, Merck & Co, Amgen, Sanofi, and Pfizer. Read More

What are the market segments for neurodegenerative diseases in Germany?

The market segments include Disease Type, Diagnosis Method, Treatment Type, and Route of Administration. Read More

What was the market size for Alzheimer's Disease in Germany in 2024?

The market size for Alzheimer's Disease was $1200.0 Million in 2024. Read More

What is the projected market size for Parkinson's Disease in Germany by 2035?

The market size for Parkinson's Disease is projected to reach $1700.0 Million by 2035. Read More

What are the expected revenues for imaging techniques in the diagnosis of neurodegenerative diseases in Germany?

Revenues for imaging techniques are expected to grow from $1200.0 Million to $2500.0 Million by 2035. Read More

What is the anticipated market size for medication as a treatment type in Germany by 2035?

The market size for medication is anticipated to reach $3200.0 Million by 2035. Read More

What is the projected revenue for oral administration routes in the treatment of neurodegenerative diseases in Germany?

Projected revenues for oral administration routes are expected to grow from $1050.0 Million to $2200.0 Million by 2035. Read More

Germany Neurodegenerative Disease Market

ID: MRFR/MED/50852-HCR

200 Pages

Vikita Thakur

Last Updated: February 06, 2026

Germany Neurodegenerative Disease Market Research Report: Size, Share, Trend Analysis By Disease Type (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Huntington's Disease), By Diagnosis Method (Neurological Examination, Imaging Techniques, Cerebrospinal Fluid Analysis, Electrophysiological Tests), By Treatment Type (Medication, Therapy, Rehabilitation, Surgical Interventions) and By Route of Administration (Oral, Injectable, Intravenous, Transdermal) - Growth Outlook & Industry Forecast 2025 To 2035

Germany Neurodegenerative Disease Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Security, Access Control and Robotics, BY Disease Type (USD Million)
  1. 4.1.1 Alzheimer's Disease
  2. 4.1.2 Parkinson's Disease
  3. 4.1.3 Multiple Sclerosis
  4. 4.1.4 Amyotrophic Lateral Sclerosis
  5. 4.1.5 Huntington's Disease
2. 4.2 Security, Access Control and Robotics, BY Diagnosis Method (USD Million)
  1. 4.2.1 Neurological Examination
  2. 4.2.2 Imaging Techniques
  3. 4.2.3 Cerebrospinal Fluid Analysis
  4. 4.2.4 Electrophysiological Tests
3. 4.3 Security, Access Control and Robotics, BY Treatment Type (USD Million)
  1. 4.3.1 Medication
  2. 4.3.2 Therapy
  3. 4.3.3 Rehabilitation
  4. 4.3.4 Surgical Interventions
4. 4.4 Security, Access Control and Robotics, BY Route of Administration (USD Million)
  1. 4.4.1 Oral
  2. 4.4.2 Injectable
  3. 4.4.3 Intravenous
  4. 4.4.4 Transdermal
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Security, Access Control and Robotics
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Security, Access Control and Robotics
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Biogen (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Eli Lilly (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Roche (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 AstraZeneca (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Merck & Co (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Amgen (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Sanofi (FR)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Pfizer (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 GERMANY MARKET ANALYSIS BY DISEASE TYPE
3. 6.3 GERMANY MARKET ANALYSIS BY DIAGNOSIS METHOD
4. 6.4 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
5. 6.5 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6. 6.6 KEY BUYING CRITERIA OF SECURITY, ACCESS CONTROL AND ROBOTICS
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF SECURITY, ACCESS CONTROL AND ROBOTICS
9. 6.9 DRIVERS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
10. 6.10 RESTRAINTS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
11. 6.11 SUPPLY / VALUE CHAIN: SECURITY, ACCESS CONTROL AND ROBOTICS
12. 6.12 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DISEASE TYPE, 2024 (% SHARE)
13. 6.13 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DISEASE TYPE, 2024 TO 2035 (USD Million)
14. 6.14 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DIAGNOSIS METHOD, 2024 (% SHARE)
15. 6.15 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
16. 6.16 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TREATMENT TYPE, 2024 (% SHARE)
17. 6.17 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
18. 6.18 SECURITY, ACCESS CONTROL AND ROBOTICS, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
19. 6.19 SECURITY, ACCESS CONTROL AND ROBOTICS, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DISEASE TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  3. 7.2.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
  4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Germany Security, Access Control and Robotics Market Segmentation

Security, Access Control and Robotics By Disease Type (USD Million, 2025-2035)

Alzheimer's Disease
Parkinson's Disease
Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Huntington's Disease

Security, Access Control and Robotics By Diagnosis Method (USD Million, 2025-2035)

Neurological Examination
Imaging Techniques
Cerebrospinal Fluid Analysis
Electrophysiological Tests

Security, Access Control and Robotics By Treatment Type (USD Million, 2025-2035)

Medication
Therapy
Rehabilitation
Surgical Interventions

Security, Access Control and Robotics By Route of Administration (USD Million, 2025-2035)

Oral
Injectable
Intravenous
Transdermal

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”